ロード中...
Fixed duration vs continuous therapy in multiple myeloma
The introduction of new drugs with less severe toxicity profiles than those of conventional antimyeloma agents allowed the evaluation of continuous therapy compared with fixed duration therapy. In transplant-eligible patients, consolidation therapy with bortezomib or bortezomib-based regimens showed...
保存先:
| 出版年: | Hematology Am Soc Hematol Educ Program |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142590/ https://ncbi.nlm.nih.gov/pubmed/29222258 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|